Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:GTHX

G1 Therapeutics (GTHX) Stock Price, News & Analysis

G1 Therapeutics logo

About G1 Therapeutics Stock (NASDAQ:GTHX)

Advanced Chart

Key Stats

Today's Range
$7.15
$7.15
50-Day Range
$7.08
$7.15
52-Week Range
$1.08
$7.19
Volume
N/A
Average Volume
1.70 million shs
Market Capitalization
$373.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Receive GTHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GTHX Stock News Headlines

Drug developer seeks $100M for new cancer treatment
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
G1 Therapeutics Inc.
Hold Rating Affirmed Amid G1 Therapeutics’ Acquisition by Pharmacosmos
See More Headlines

GTHX Stock Analysis - Frequently Asked Questions

G1 Therapeutics, Inc. (NASDAQ:GTHX) released its quarterly earnings data on Wednesday, May, 1st. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.01. The firm had revenue of $14.48 million for the quarter, compared to analyst estimates of $15.21 million. G1 Therapeutics had a negative trailing twelve-month return on equity of 136.98% and a negative net margin of 76.93%.
Read the conference call transcript
.

G1 Therapeutics (GTHX) raised $101 million in an initial public offering on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that G1 Therapeutics investors own include Meta Platforms (META), Advanced Micro Devices (AMD), Moderna (MRNA), Novavax (NVAX), Pfizer (PFE), NVIDIA (NVDA) and Alibaba Group (BABA).

Company Calendar

Last Earnings
5/01/2024
Today
7/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GTHX
Employees
170
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$47.97 million
Pretax Margin
-73.83%

Debt

Sales & Book Value

Annual Sales
$58.20 million
Price / Cash Flow
N/A
Book Value
$0.68 per share
Price / Book
10.51

Miscellaneous

Free Float
49,087,000
Market Cap
$373.81 million
Optionable
Optionable
Beta
1.66

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:GTHX) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners